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in rats with cachexia associated with 
chronic kidney disease. 14 
 In conclusion, despite reports of the 
short- and intermediate-term success of 
ghrelin administration in treating 
anorexia and cachexia in ESRD patients, 
we must await results of studies on its 
long-term eK  cacy in improving appetite, 
weight gain, and lean body mass as well as 
quality of life. 
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 - ere is substantial evidence that arterial 
under( lling, due to either decreased car-
diac output, e.g., heart failure, or systemic 
arterial vasodilation, e.g., cirrhosis, is 
associated with activation of the neurohu-
moral axis, including the sympathetic 
nervous system, the renin – angiotensin 
system, and arginine vasopressin (AVP). 
This neurohumoral response involves 
compensatory systemic vasoconstriction 
and renal sodium and water restriction in 
order to attenuate the arterial under( lling, 
that is, the so-called decreased e: ective 
arterial blood volume. What is not known 
is whether there is an interaction at the 
cellular and molecular levels between 
these responses to arterial under( lling. 
 Li  et al. 1 (this issue) provide experimen-
tal evidence indicating an importance 
of angiotensin II in normal AVP-medi-
ated urinary concentration. There are 
 several potential mechanisms whereby 
 angiotensin II could modulate water 
 homeostasis, and thus angiotensin II 
receptor knockout (KO) mice would be 
expected to have impaired urine-concen-
trating capacity. - ere is substantial evi-
dence that angiotensin II stimulates the 
thirst center in the brain, thereby leading 
to increased thirst and water intake. 2 
- us, the angiotensin II type 1a (AT 1a ) 
receptor KO mice might be expected to 
decrease their water intake unless other 
intervening e: ects occur. In this regard, 
Li  et al. 1 demonstrated that these KO mice 
actually have an increase, not a decrease, 
in water intake. Although somewhat con-
troversial, there is evidence that angio-
tensin II may stimulate AVP release. 3,4 Li 
 et al. 1 did demonstrate a decrease in basal 
plasma AVP concentrations in AT 1a 
receptor KO mice, as compared with wild-
type mice. - is, however, has not been a 
consistent ( nding in these AT 1a receptor 
KO mice. 5 In order to demonstrate partial 
central diabetes insipidus in the AT 1a KO 
mice, for which Li  et al. 1 propose a role, it 
would be necessary to perform fluid 
restriction — which maximally concen-
trates urine in wild-type mice — and then 
administer exogenous AVP . Exogenous 
AVP would not increase urinary 
 osmolality further aP er such F uid restric-
tion in wild-type mice; however, a further 
increment in urinary osmolality aP er F uid 
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 Mice deficient in the angiotensin II type 1a (AT 1a ) receptor demonstrate 
a vasopressin-resistant nephrogenic diabetes insipidus. These knockout 
mice exhibit a threefold increase in 24-h urine excretion. Neither 2 weeks 
of exogenous vasopressin nor 5 days of fluid restriction reversed this 
polyuric state. This nephrogenic diabetes insipidus was associated with 
reductions in adenylyl cyclase protein and in the phosphorylated 
mitogen-activated protein kinase extracellular signal – regulated kinase 
1 / 2 . The results support an important interaction between vasopressin 
and angiotensin II in maximal urinary concentration. 
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restriction with exogenous AVP would be 
expected in mice with partial central dia-
betes insipidus. As these studies were not 
performed, evidence for a role of AVP-
responsive partial central diabetes insip-
idus cannot be established in these AT 1a 
KO mice. 
 A hemodynamic role of angiotensin II 
was apparent in these KO mice because 
their arterial blood pressures were sig-
ni( cantly decreased compared with those 
of wild-type mice. Although renal hemo-
dynamics were not reported in these KO 
mice, the observed decrease in renal arte-
rial pressure was a likely factor in the 
observed diminished solute diuresis in 
response to sucrose administration, as 
compared with that of wild-type mice. In 
any case, increased solute excretion was 
excluded as a factor in the urine-concen-
trating defect in these AT 1a KO mice. 
 What was very clear in the Li  et al. 1 
study was the presence of an AVP-resist-
ant nephrogenic diabetes insipidus in 
these AT 1a KO mice. The lower blood 
pressure in these KO mice could stimulate 
thirst, independent of angiotensin II, and 
increased water ingestion. Increased water 
intake has been shown to cause a urine-
concentrating defect. 6 Decreasing the 
water intake in the AT 1a KO mice to the 
level ingested by wild-type mice for 24  h 
or 5 days did not, however, correct the 
urine-concentrating defect. Although 
these results do not support a polydipsia-
related urine-concentrating defect, per-
haps a longer period of normalizing F uid 
intake to the level ingested by wild-type 
mice may be necessary to improve the 
urine-concentrating defect in AT 1a KO 
mice, which have had lifelong poly-
dipsia. 
 Of considerable interest was the 
observed defect in AVP signaling and 
aquaporin 2 (AQP2) traK  cking to the 
apical membrane in the inner medulla 
of the AT 1a KO mice. Although there 
was no evidence of decreased V 2 vaso-
pressin receptor binding in the inner 
medulla, there was a decline in adenylyl 
cyclase III and V / VI protein and in the 
phosphorylated mitogen-activated 
 protein kinase extracellular signal –
 regulated kinase 1 / 2 . In contrast to the 
defect in the AVP-mediated AQP2 traf-
( cking, the AVP stimulation of AQP2 
protein expression was less disparate as 
compared with that in the wild-type 
mice. This result suggests that angi-
otensin II may exert a more important 
interaction with AVP in AQP2 traK  ck-
ing to the apical membrane of the prin-
cipal cells of the medullary collecting 
duct as compared with the AVP-medi-
ated upregulation of AQP2 expression 
( Figure 1 ). 
 - ere are previously published  in vitro 
and  in vivo results that suggest an interac-
tion between AVP and angiotensin II. 
Angiotensin has been shown to enhance 
the  in vitro AVP-dependent cAMP (cyclic 
adenosine monophosphate) accumula-
tion in Chinese hamster ovary cells trans-
fected with AT 1a and V 2 receptors. 7 In 
primary cell culture of inner medullary 
collecting duct cells, angiotensin II and 
Desmopressin acetate both increased 
phosphorylation of AQP2 protein and its 
trafficking to the apical membrane. 8 
Moreover, angiotensin receptor blockade 
 in vitro has been shown to decrease uri-
nary concentration and AQP2. 9 Because 
there are many clinical disorders of water 
homeostasis in which arterial under( lling 
is present and associated with both 
increased AVP and angiotensin II, the 
potential interaction of these hormones 
at the molecular and cellular level has 
important implications. 10 
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 Figure 1  |  Potential pathway for interaction between angiotensin II and arginine vasopressin 
in the modulation of urinary concentration. AQP2, aquaporin 2, cAMP, cyclic adenosine 
monophosphate. 
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